Recombinant cynomolgus TNFRSF18 protein, His-tagged
Cat.No. : | Tnfrsf18-01C |
Product Overview : | Recombinant cynomolgus TNFRSF18 fused with His tag was expressed in HEK293. |
Availability | February 15, 2025 |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
- Download
Description : | TNFRSF18 played an important role in many functions. |
Source : | HEK293 |
Species : | cynomolgus |
Tag : | His |
Form : | PBS (pH = 7.4), 5 % - 8 % trehalose and mannitol are added |
Purity : | >90% monomer by SEC-HPLC |
Storage : | For short term, storage it at +4 centigrade, For long term storage, prepare aliquots with 20% glycerol and store at -20 centigrade. Avoid freeze/thaw cycles. |
Publication : |
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy (2022)
|
Gene Name : | TNFRSF18 tumor necrosis factor receptor superfamily member 18 [ Macaca fascicularis ] |
Official Symbol : | TNFRSF18 |
Synonyms : | tumor necrosis factor receptor superfamily member 18; tumor necrosis factor receptor superfamily, member 18 |
Gene ID : | 102146362 |
Chromosome Location : | chromosome: 1 |
Pathway : | Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem |
Products Types
◆ Recombinant Protein | ||
TNFRSF18-663M | Recombinant Mouse TNFRSF18 Protein, Fc-tagged | +Inquiry |
TNFRSF18-1019C | Recombinant Cynomolgus TNFRSF18 Protein (Met1-Glu155), His-tagged | +Inquiry |
TNFRSF18-662M | Recombinant Mouse TNFRSF18 Protein | +Inquiry |
TNFRSF18-9477M | Recombinant Mouse TNFRSF18 Protein, His (Fc)-Avi-tagged | +Inquiry |
TNFRSF18-2769H | Recombinant Human TNFRSF18 Protein, His-tagged | +Inquiry |
◆ Lysates | ||
TNFRSF18-1143HCL | Recombinant Human TNFRSF18 cell lysate | +Inquiry |
TNFRSF18-1245RCL | Recombinant Rat TNFRSF18 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThis flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.
Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.
The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.
Q&As (5)
Ask a questionClinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.
As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.
Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.
TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.
Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.
Ask a Question for All TNFRSF18 Products
Required fields are marked with *
My Review for All TNFRSF18 Products
Required fields are marked with *
Inquiry Basket